Deal Library / Pharma BD Deal Intelligence

AbbVie Inc. — Pharma Deals

The Pharma Closeout tracks 37 deals, $220.4B in disclosed deal value, 17 with a post-close Outcome Score for AbbVie Inc..

Median Critic Score: 78  ·  Median Outcome Score: 59

Best outcome: AbbVie Inc. / Boehringer Ingelheim GmbH (95)  ·  Weakest outcome: AbbVie Inc. / Stemcentrx, Inc. (9)

All 37 deals

• AbbVie Inc. / Boehringer Ingelheim GmbH — 2016 · $2.2B · Worked — the deal delivered on its rationale.
• AbbVie Inc. / Genmab A/S — 2020 · $3.9B · Worked — the deal delivered on its rationale.
• AbbVie Inc. / Pharmacyclics Inc. — 2015 · $21.0B · Worked — the deal delivered on its rationale.
• AbbVie Inc. / Apogee Therapeutics, Inc. — 2026 · $10.9B · Largely worked — most objectives met.
• AbbVie Inc. / ImmunoGen Inc. — 2023 · $10.1B · Largely worked — most objectives met.
• AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. — 2024 · $2.0B · Largely worked — most objectives met.
• AbbVie Inc. / MedinCell S.A. — 2024 · $1.9B · Largely worked — most objectives met.
• AbbVie Inc. / Allergan, Inc. — 2019 · $63.0B · Largely worked — most objectives met.
• AbbVie Inc. / EvolveImmune Therapeutics Inc. — 2024 · $1.5B · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Aliada Therapeutics — 2024 · $1.4B · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Synlogic — 2016 · $18M · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Cerevel Therapeutics — 2023 · $8.7B · Underwhelmed — fell short of the thesis.
• AbbVie Inc. / Shire plc — 2014 · $54.0B · Underwhelmed — fell short of the thesis.
• AbbVie Inc. / I-Mab — 2020 · $2.9B · Did not work — the deal failed to deliver.
• AbbVie Inc. / argenx SE — 2016 · $685M · Did not work — the deal failed to deliver.
• AbbVie Inc. / Stemcentrx Inc. — 2012 · $5.8B · Did not work — the deal failed to deliver.
• AbbVie Inc. / Stemcentrx, Inc. — 2016 · $9.8B · Did not work — the deal failed to deliver.
• AbbVie Inc. / Haisco Pharmaceutical Group Co., Ltd. — 2026 · $745M
• AbbVie Inc. / Kestrel Therapeutics, Inc. — 2026 · $1.4B
• AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. — 2025 · $1.2B
• AbbVie Inc. / Ichnos Glenmark Innovation (IGI) — 2025 · $1.9B
• AbbVie Inc. / Capstan Therapeutics, Inc. — 2025 · $2.1B
• AbbVie Inc. / Celsius Therapeutics Inc. — 2024 · $250M
• AbbVie Inc. / Landos Biopharma Inc. — 2024 · $212M
• AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd. — 2024 · $1.7B
• AbbVie Inc. / Mitokinin, Inc. — 2023 · $655M
• AbbVie Inc. / Aldeyra Therapeutics, Inc. — 2023 · $400M
• AbbVie Inc. / DJS Antibodies Ltd. — 2022 · $255M
• AbbVie Inc. / Sosei Group Corp. (Sosei Heptares) — 2022 · $1.3B
• AbbVie Inc. / Syndesi Therapeutics SA — 2022 · $1.0B
• AbbVie Inc. / Calico Life Sciences LLC — 2021 · $1.0B
• AbbVie Inc. / REGENXBIO Inc. — 2021 · $1.8B
• AbbVie Inc. / Harpoon Therapeutics, Inc. — 2019 · $510M
• AbbVie Inc. / Boehringer Ingelheim GmbH (Risankizumab buyout) — 2019 · $595M
• AbbVie Inc. / Halozyme Therapeutics, Inc. (ENHANZE platform) — 2015 · $1.2B
• AbbVie Inc. / Infinity Pharmaceuticals, Inc. — 2014 · $805M
• AbbVie Inc. / Calico LLC — 2014 · $1.5B

← Deal Library  ·  Interactive search  ·  How we score deals